Survival curves for patients with systemic light chain amyloidosis stratified by NT-proBNP response or progression at six months

In the international series of 816 patients from seven centers, staging cardiac biomarkers were available for 53 percent (432/816). Of these, 24 percent were stage 1 (both NT-proBNP p ≤332 ng/L and cardiac troponin T (cTnT) p ≤0.035 ng/mL or cTnI p ≤0.1 ng/mL), 52 percent stage 2 (NT-proBNP >332 ng/L or cTnT >0.035 ng/mL or cTnI >0.1 ng/mL), and 24 percent stage 3 (both NT-proBNP >332 ng/L and cTnT >0.035 ng/mL or cTnI >0.1 ng/mL). In these survival curves, results for 377 patients with baseline NT-proBNP greater than or equal to 650 ng/L are shown according to NT-proBNP response or progression at six months.^[1]